Eli Lilly halted a large-scale trial of the drug solanezumab after it failed to achieve significant results in slowing cognitive decline in patients with mild Alzheimer’s symptoms. Solanezumab is an antibody intended to reduce the buildup of amyloid plaques in the brain.